ENO2 and small cell lung carcinoma: NSE is one of the most reliable serum markers for the diagnosis and prognosis of small-cell lung cancer (SCLC), and a meta-analysis of 16 studies showed that elevated pretreatment serum NSE predicted poorer OS for SCLC patients, with a combined HR of 1.78 (Tian et al., 2020).